
Medtronic

Onyx Frontier[™] DES












Engineered to deliver

Onyx Frontier DES introduces an enhanced delivery system[†] designed to take the acute performance of Resolute Onyx[™] DES even further.

Enhanced delivery system[†] features:



Dual-flex balloon provides increased flexibility and is comprised of a unique blend of two layers²:

- Inner layer enhances flexibility²
- Outer layer maintains strength³

This results in a **thinner balloon**[‡] with the same rated burst pressure (RBP) as Resolute Onyx DES.³



The dual-flex balloon enables a **7.5% lower** crossing profile than Resolute Onyx DES.¹






Deliverability comparison

3.0 mm DES



2-D track maximum force (gf scaled) Lower is better




An updated manufacturing process applied to the outer shaft results in a 29% more flexible catheter¹ (compared to Resolute Onyx DES) for improved deliverability.⁴




Different by design

Onyx Frontier DES builds off the legacy of Resolute Onyx DES, featuring the same stent design differentiators that provide the conformability,⁵ visibility,⁶ fast healing,⁷ and size matrix you've come to rely on.

In comparison to laser-cut drug-eluting stents, only Medtronic DES are made from a single wire to enable a fluid range of motion and the conformability needed for superior strut apposition.5



The platinum-iridium core within Onyx
Frontier DES is **more visible** than competitive
DES, while enabling greater radial strength
with thin struts.§6




The zotarolimus drug inhibits neointimal growth,⁸ while the BioLinx[™] biocompatible polymer – the only polymer specifically designed for a DES – promotes faster healing.⁷

Only Medtronic offers DES in 2.0 mm to 5.0 mm sizes, with overexpansion capabilities up to 6.0 mm, $^{\Omega}$ to treat the broadest range of coronary vessel diameters.

Platform	Diameter (mm)	Stent length (mm)									MSID ^Ω (mm)
Small vessels	2.00	8	12	15	18	22	26	30			3.50
	2.25	8	12	15	18	22	26	30	34	38	3.50
	2.50	8	12	15	18	22	26	30	34	38	3.50
Medium vessels	2.75	8	12	15	18	22	26	30	34	38	4.00
	3.00	8	12	15	18	22	26	30	34	38	4.00
Large vessels	3.50	8	12	15	18	22	26	30	34	38	5.00
	4.00	8	12	15	18	22	26	30	34	38	5.00
Extra-large vessels	4.50		12	15	18	22	26	30			6.00
	5.00		12	15	18	22	26	30			6.00

Four platforms specifically designed to meet the unique needs of each vessel size.



Optimised for complex PCI

An exclusive set of design features and meaningful clinical data inherited from Resolute Onyx DES provide support for your most challenging cases.

Bifurcation PCI

- Other DES feature irregular cell shapes, which may obstruct wire or catheter advancement through the cell's opening
- Round struts create a smooth passage when accessing the side branch, while lowering the propensity to catch⁹

Rounded struts



Onyx Frontier DES


SYNERGY[™] MONORAIL EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM


Square struts



XIENCE™
EVEROLIMUS
ELUTING
CORONARY STENT
SYSTEMS

(Cross-section of actual stents)





4.50-5.00 mm expand up to 6.00 mm $^{\!\Omega}$ while maintaining structural integrity

Left main and other extra-large vessel PCI (4.50-5.00 mm)

- Specifically designed with additional crowns and thicker struts^{††} to provide the radial strength needed for extralarge vessels¹⁰
- Maintains a low profile, 10 allowing for 5 Fr compatibility
- ROLEX Registry showed Resolute Onyx DES was safe and effective in left main PCI in a complex patient population¹¹


59% multivessel disease


53% acute coronary syndrome

30%

diabetic

Low 5.1% TLF, 2.0% TLR, and 1.1% ST at one year





2.00-2.50 mm expand up to 3.50 mm^o with minimal foreshortening for tapered and extra-small vessels¹⁴

Extra-small vessels

(2.00-2.50 mm)

- 2.0 mm offers the lowest crossing profile of any DES¹²
- Demonstrated 2% target lesion revascularisation and 0% stent thrombosis at one year in a complex, smallvessel population¹³



Onyx ONE Global Trial 1,003 Resolute Onyx DES patients studied

COMPLEX PATIENTS

39% AF patients

diabetic patients patients

COMPLEX LESIONS

46% 38 mm B2/C moderate average

to severe calcified lesions

lesions stented length

- Indication is based on the results from the Onyx ONE Global Trial, which evaluated real-world, complex, HBR patients on 1-month DAPT treated with a Resolute Onyx DES or a BioFreedom™* DCS
- The data is intended to better inform short-DAPT decisions in these patients, including those at high risk of thrombotic events¹⁵
- Results showed that Resolute Onyx DES was safe and effective¹⁵

Medtronic

99 Hereford Street Brampton, Ontario, L6Y 0R3 Toll-free: 800.268.5346 Tel: 905.460.3800

Third-party brands are trademarks of their respective owners.

[†]Stent delivery system updates were implemented on the 2.0-4.0 mm Onyx Frontier DES diameter.

[‡]Compared to Resolute Onyx 3.0mm balloon design.

Onyx Frontier DES has the same platinum-iridium core as Resolute Onyx DES ^ΩStents should not be expanded to a diameter beyond the maximum labeled diameter

listed per the IFU. Post-dilation required for overexpansion. ^{††}Compared to 2.0-4.0 mm sizes.

[#]May not be indicative of clinical performance.

 $^{^1}$ Based on bench test data. ‡ Compared to Resolute Onyx DES. n = 5 of each 3.0 mm DES. 2 Based on bench test data. ‡ Compared to Resolute Onyx balloon (3.0 mm). n = 10 of each balloon.

each balloon.

3 Resolute Onyx DES and Onyx Frontier DES IFUs.

4 Based on bench test data (method D00117002).^{‡†} n = 7 of each DES.

5 Based on modeling of 3.0 mm stents.^{‡†} Evaluated Resolute Onyx DES, Synergy DES, and XIENCE Alpine DES (Multi-Link 8 BMS platform).

6 Based on bench test data.^{‡†} n = 3 of each 3.0 mm DES: Onyx Frontier DES, Orsiro DES, XIENCE DES, Synergy DES, Ultimaster DES.

Roleder T. Kedhi E. Berta B. et al. Short-term stent coverage of second-generation Tolkieder I, Kedin E, Berla B, et al. Short-term Stein Coverage of section d-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.

Syeh RW, Silber S, Chen L, et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. February

^{2017:10(3):247-254.}

⁹Based on bench test data.^{‡‡} n = 10 of each 3.0 mm platform: Onyx Frontier, Multi-Link 8

⁹Based on bench test data.^{‡‡} n = 10 of each 3.0 mm platform: Onyx Frontier, Multi-Link 8 (Abbott), Omega (Boston Scientific).

¹⁰Based on bench test data.^{‡‡} Minimum n = 3 of each Onyx Frontier stent platform.

¹¹Tarantini G, Fovino LN, Varbella F, et al. A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study. EuroIntervention. Published online August 31, 2022.

¹²Based on bench test data.^{‡‡} n = 5 of each DES (2.0 mm and 2.25 mm): Onyx Frontier DES, Resolute Onyx DES, Synergy XD DES, Xience Skypoint DES.

¹³Cuellas C, et al. Use of a Zotarolimus-eluting stent for small vessel disease (DISCO 9 Study). Presented at PCR 2021.

¹⁴Based on bench test data.^{‡‡} n = 10 Resolute Onyx 2.0 mm DES

Massed on bench test data.[±] n = 10 Resolute Onyx 2.0 mm DES.
 Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.